fabp

BMS309403 is a potent and selective inhibitor of adipocyte fatty acid binding protein aFABP. It improves endothelial function in apolipoprotein E-deficient mice and cultured human endothelial cells. It interacts with the fatty acid binding pocket inside the protein and competitively inhibits the binding of endogenous fatty acids.

FABP-IN-2, a novel ligand for FABP3, demonstrates inhibition of both FABP3 and FABP4 with IC50 values of 1.16 μM and 4.27 μM, respectively.

FABPs ligand 6 (MF6) is a selective inhibitor of FABP5 and FABP7 that reduces levels of oxidative stress in the mouse spinal cord as well as lipopolysaccharide-stimulated interleukin-1β and tumor necrosis factor α accumulation in primary astrocyte cultures.FABPs ligand 6 has a potent protective function in oligodendrocytes of EAE mice through FABP5 inhibition. mitochondria with a strong protective function.

FABP4-IN-2 (Compd 10g), a selective and orally active FABP4 inhibitor, exhibits K i values of 0.51 μM for FABP4 and 33.01 μM for FABP3, demonstrating its specificity towards FABP4. It is utilized in research investigating inflammatory diseases [1].

FABP4 5-IN-4 (compound E1) effectively inhibits FABP 4 and FABP 5, displaying IC50 values of 3.78 μM and 5.72 μM, respectively. It is significant in the management of metabolic disorders such as diabetes mellitus [1].

FABP4 5-IN-5 (compound D9) serves as a potent inhibitor of both FABP 4 and FABP 5, demonstrating IC50 values of 4.68 μM and 10.72 μM, respectively. It is notably effective in addressing metabolic disorders such as diabetes mellitus [1].

FABP4-IN-4 (Compound 30) is an orally effective inhibitor of FABP, with an IC50 value of 1.18 μM against FABP1. In a mouse model of diet-induced obesity, FABP4-IN-4 improves glucose tolerance, reduces levels of blood sugar, lipids, and liver inflammation markers, alleviates hepatic steatosis, and exhibits anti-inflammatory activity.

STK-15 is a candidate for use as an inhibitor of fatty acid binding protein 5 (FABP5).